Menu
NASP

All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

Learn about the burden of influenza, guideline updates for treatment, timing of antiviral initiation and more.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

SHOW SEARCH

IBD: Medication and Patient Management

To Participate

To participate in this continuing education activity:

  1. Review the activity description and objectives.
  2. View the activity.
  3. Complete the online post-test and activity evaluation.

This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.


 

A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities
 

Activity Description

Inflammatory Bowel Disease (IBD) describes a group of chronic conditions such as ulcerative colitis, Crohn's Disease and indeterminate colitis, all of which can have a severe impact on a patient's quality of life. IBD can cause additional complications and systemic manifestations, resulting in hospitalization. There are numerous factors to consider in selecting optimal drug therapies for IBD. Coordination and continuity of patient care is essential in IBD. This activity addresses treatment goals, options for therapy, monitoring parameters and the pharmacist's role in IBD therapy management.

Learning Objectives

The target audience for this activity is pharmacists. Upon completion of this activity, participants will be able to:

  • Review inflammatory bowel disease (IBD).
  • List current treatment guidelines and practices for managing Crohn’s Disease and Ulcerative Colitis (UC).
  • Describe the pharmacology of medication interventions for IBD delineating side effects and relevant drug interactions.
  • Discuss treatment appropriateness and medication toxicity.
  • Recognize monitoring tools for disease state progression.
  • Outline potential special needs/social issues impacting patient’s with IBD.
  • Discuss the importance of working effectively in collaborative teams to provide patient education and ongoing support to improve access and adherence to therapy.

Faculty

Kami Roake, PharmD
Gastroenterology & Rheumatology Pharmacist
University of Utah Hospitals & Clinics

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Kami Roake has no relevant commercial or financial relationships to disclose.

CE Accreditation

Release Date: May 1, 2020
Expiration Date: May 1, 2023

Pharmacists

This CE activity is jointly provided by ProCE, Inc. and NASP. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-218-H01-P has been assigned to this knowledge-based home-study CE activity. This activity is approved for 2.25 contact hour (0.225 CEU) in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given.

Funding

No external support has been received for this activity.

 

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.